Loading clinical trials...
Loading clinical trials...
A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined With MOR00208 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)
Conditions
Interventions
Tafasitamab
Lenalidomide
Locations
57
United States
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center
Bakersfield, California, United States
UCLA - David Geffen School of Medicine
Los Angeles, California, United States
Cancer Care - Torrance Memorial Physician Network
Redondo Beach, California, United States
Central Coast Medical Oncology Corporation
Santa Maria, California, United States
St. Mary's Hospital And Regional Medical Center
Grand Junction, Colorado, United States
Norwalk Hospital
Norwalk, Connecticut, United States
Start Date
March 29, 2016
Primary Completion Date
November 14, 2022
Completion Date
April 19, 2023
Last Updated
October 23, 2023
NCT06395103
NCT05272384
NCT05139017
NCT01804686
NCT07443514
NCT05755087
Lead Sponsor
MorphoSys AG
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions